Company intelligence / Profile preview

Zenith

Calgary, Alberta, Canada

Ownership: Private
Development stage: Other

Overview

Lead asset ZEN-3694 (BET inhibitor) has received FDA Fast Track designation for NUT carcinoma and is in Phase 2 studies for several cancer types. Early clinical results in combination regimens show signs of efficacy in hard-to-treat cancers. Collaborations ongoing with NCI and others.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

PfizerMerckNewsoara BioPharmNational Cancer Institute (NCI)University of California San Francisco (UCSF)

Beyond the preview

Go deeper on Zenith.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zenith.

Explore the full profile